Sherilyn Russell, MD
Endocrinology, Diabetes & Metabolism · Grosse Pointe, MINPI 1386859148
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,600 of the $26,447 with a category attached, or 85.5%. Amgen accounts for 90.1% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $23,655, more than ten times the $493 reported in 2019.
Across 178 payments — averaging $148.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$24K
- Abbott$371
- Sanofi-aventis U.S. LLC$295
- Novo Nordisk$263
- Dexcom, Inc.$236
- Insulet Corporation$160
- plus $1K from 30 others
What the payments were for
- Speaking & faculty fees$22,60085%
- Travel & lodging$2951%
- Food & beverage$3,49713%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 43 | $23,842 |
| Abbott | 22 | $371 |
| Sanofi-aventis U.S. LLC | 10 | $295 |
| Novo Nordisk | 14 | $263 |
| Dexcom, Inc. | 13 | $236 |
| Insulet Corporation | 8 | $160 |
| Lilly USA, LLC | 6 | $116 |
| Amneal Pharmaceuticals LLC | 6 | $107 |
| Medtronic(2 entities) | 6 | $104 |
| Boehringer Ingelheim | 4 | $78 |
| AbbVie | 4 | $76 |
| BETA Bionics, Inc. | 4 | $68 |
| Bayer | 3 | $64 |
| Mannkind Corporation | 2 | $60 |
| Radius Health, Inc. | 3 | $55 |
| AstraZeneca(2 entities) | 3 | $53 |
| Recordati_rare_diseases_inc. | 2 | $48 |
| Ascensia Diabetes Care US Inc. | 2 | $45 |
| Corcept Therapeutics | 2 | $38 |
| Amryt Pharma Holdings Ltd | 2 | $38 |
| Amphastar Pharmaceuticals, Inc. | 2 | $36 |
| Embecta Corp. | 2 | $35 |
| Averitas Pharma Inc. | 1 | $30 |
| Soleno Therapeutics, Inc. | 1 | $29 |
| Antares Pharma, Inc. | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $20 |
| IBSA Pharma Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Alvogen Inc | 1 | $18 |
| Merck | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Tandem Diabetes Care, Inc. | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,447 in reported general payments places this provider in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 345 | $643,478 |
| MounjaroTirzepatide | 109 | $173,071 |
| TrulicityDulaglutide | 100 | $163,772 |
| JardianceEmpagliflozin | 87 | $120,359 |
| Tresiba Flextouch U-100Insulin Degludec | 108 | $103,795 |
| Teriparatide | 14 | $59,217 |
| Novolog FlexpenInsulin Aspart | 146 | $57,644 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $51,036 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $47,120 |
| Humalog Kwikpen U-100Insulin Lispro | 87 | $42,237 |
| JanuviaSitagliptin Phosphate | 23 | $36,526 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 200 | $35,793 |
| TymlosAbaloparatide | 13 | $34,671 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $26,044 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 202 | $24,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $263 | $646,172364 claims |
| Lilly USA, LLCMounjaro, Trulicity | $116 | $336,842209 claims |
| Boehringer IngelheimJardiance | $78 | $120,35987 claims |
| Alvogen IncTeriparatide | $18 | $59,21714 claims |
| MerckJanuvia | $14 | $36,52623 claims |
| Radius Health, Inc.Tymlos | $55 | $34,67113 claims |
| AstraZenecaFarxiga | $53 | $12,93922 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $107 | $10,082804 claims |
| AbbVieSynthroid | $76 | $8,08183 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Grosse Pointe
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
- Kara HoisingtonLansing$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.